JP2010216917A - Ed評価方法 - Google Patents
Ed評価方法 Download PDFInfo
- Publication number
- JP2010216917A JP2010216917A JP2009062536A JP2009062536A JP2010216917A JP 2010216917 A JP2010216917 A JP 2010216917A JP 2009062536 A JP2009062536 A JP 2009062536A JP 2009062536 A JP2009062536 A JP 2009062536A JP 2010216917 A JP2010216917 A JP 2010216917A
- Authority
- JP
- Japan
- Prior art keywords
- glutathione
- subject
- concentration
- mild
- significantly higher
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title description 7
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 48
- 208000010228 Erectile Dysfunction Diseases 0.000 claims abstract description 33
- 201000001881 impotence Diseases 0.000 claims abstract description 33
- 108010024636 Glutathione Proteins 0.000 claims abstract description 24
- 229960003180 glutathione Drugs 0.000 claims abstract description 23
- 239000012472 biological sample Substances 0.000 claims description 4
- 238000011156 evaluation Methods 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000003296 saliva Anatomy 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 210000005226 corpus cavernosum Anatomy 0.000 description 1
- PZAYJNNTMOGLPX-UHFFFAOYSA-N cyclopenta[c]pyrazole Chemical class N1=NC2=CC=CC2=C1 PZAYJNNTMOGLPX-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000001856 erectile effect Effects 0.000 description 1
- 230000009986 erectile function Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004092 self-diagnosis Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
【解決手段】 被験者の生体試料中のグルタチオン濃度を測定し、この濃度が健常者のグルタチオン濃度より有意に高い場合に、被験者の勃起不全(ED:erectile dysfunction)の程度が軽度であると評価する。
【選択図】 図1
Description
Claims (1)
- 被験者の生体試料中のグルタチオン濃度を測定し、この濃度が健常者のグルタチオン濃度より有意に高い場合に、被験者の勃起不全(ED:erectile dysfunction)の程度が軽度であると評価することを特徴とするED評価方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009062536A JP5208028B2 (ja) | 2009-03-16 | 2009-03-16 | Ed評価方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009062536A JP5208028B2 (ja) | 2009-03-16 | 2009-03-16 | Ed評価方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010216917A true JP2010216917A (ja) | 2010-09-30 |
JP5208028B2 JP5208028B2 (ja) | 2013-06-12 |
Family
ID=42975931
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009062536A Expired - Fee Related JP5208028B2 (ja) | 2009-03-16 | 2009-03-16 | Ed評価方法 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5208028B2 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108519770B (zh) * | 2018-04-27 | 2020-10-27 | 东北大学 | 一种浮选过程运行控制的实验平台 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001507696A (ja) * | 1996-12-31 | 2001-06-12 | アンチオキシダント ファーマシューティカルズ コーポレーション | グルタチオンの医薬製剤およびその投与方法 |
JP2004131482A (ja) * | 2002-08-21 | 2004-04-30 | Chee Keung Chung | ガノデルマルシダム胞子を用いた抗老化/更年期症状緩和 |
WO2008106640A1 (en) * | 2007-03-01 | 2008-09-04 | Cedars-Sinai Medical Center | Antioxidant polymers containing [1,2]-dithiolane moieties and uses thereof |
-
2009
- 2009-03-16 JP JP2009062536A patent/JP5208028B2/ja not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001507696A (ja) * | 1996-12-31 | 2001-06-12 | アンチオキシダント ファーマシューティカルズ コーポレーション | グルタチオンの医薬製剤およびその投与方法 |
JP2004131482A (ja) * | 2002-08-21 | 2004-04-30 | Chee Keung Chung | ガノデルマルシダム胞子を用いた抗老化/更年期症状緩和 |
WO2008106640A1 (en) * | 2007-03-01 | 2008-09-04 | Cedars-Sinai Medical Center | Antioxidant polymers containing [1,2]-dithiolane moieties and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
JP5208028B2 (ja) | 2013-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Devaux et al. | Diagnostic and prognostic value of circulating micro RNA s in patients with acute chest pain | |
Karlík et al. | Markers of oxidative stress in plasma and saliva in patients with multiple sclerosis | |
US10132809B2 (en) | Differential expression of protein markers for the diagnosis and treatment of eosinophilic esophagitis | |
RU2713112C2 (ru) | Способы и средства для диагностики гриппа | |
Banne et al. | Reduced level of serum thiols in patients with a diagnosis of active disease | |
JP2016118568A (ja) | 酸化状態の測定及び使用方法 | |
JP6449247B2 (ja) | 移植拒絶反応、神経変性疾患又はうつ病と特に関連する潜在的炎症のインビトロ早期検出方法 | |
CN105525029A (zh) | 反映男性精子活力的精浆piRNA标志物或其组合及应用 | |
Huang et al. | Sensitive tracking of circulating viral RNA through all stages of SARS-CoV-2 infection | |
Liu et al. | Prevalence and risk factors of CKD in Chinese patients with periodontal disease | |
Goto et al. | Can wound exudate from venous leg ulcers measure wound pain status?: a pilot study | |
Deminice et al. | Human and rodent skeletal muscles express angiotensin II type 1 receptors | |
JP5208028B2 (ja) | Ed評価方法 | |
Trueba et al. | Effects of academic exam stress on nasal leukotriene B4 and vascular endothelial growth factor in asthma and health | |
Nancey et al. | Urinary neopterin is a valuable tool in monitoring Crohn's disease activity | |
JP6360848B2 (ja) | ライソゾーム病3疾患責任酵素の迅速マススクリーニング検査法 | |
KR101381079B1 (ko) | 나노입자의 독성 평가방법 | |
KR102281793B1 (ko) | 혈중 메타볼리즘을 이용한 건강 상태 정보 제공 장치 및 그 방법 | |
CN103344768B (zh) | 缺血性心脏病检测试剂盒及其应用 | |
Grover et al. | Clinical relevance of the advanced microbiologic and biochemical investigations in periodontal diagnosis: a critical analysis | |
Rawdhah et al. | Salivary lactate dehydrogenase and salivary total protein as potential biomarkers for screening periodontal disease | |
Xie et al. | A preliminary study of the effects of the tilburg frailty indicator, frailty phenotype, and silver nanoparticle-silver needle therapy in senile inpatients with frailty | |
Brady et al. | Cyanide-nitroprusside colorimetric assay: A rapid colorimetric screen for urinary cystine | |
US7759086B2 (en) | Diagnostic method for chronic fatigue syndrome by measuring elastase | |
RU2773830C1 (ru) | Способ диагностики расстройства вегетативной нервной системы у девочек дошкольного возраста, ассоциированного с избыточной контаминацией биосред детей марганцем |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120117 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121030 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20121031 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121225 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130129 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130219 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160301 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |